Verona Pharma plc   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (2005)

Organization Overview

First Clinical Trial
2014
NCT02307162
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Verona Pharma Inc | Verona Pharma plc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Coronavirus Infections (Phase 2)

Cystic Fibrosis (Phase 2)

Disease (Phase 1)

Fibrosis (Phase 2)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 6